DBV Technologies S.A. 8-K

What Happened
DBV Technologies S.A. (DBVT) filed a Form 8-K (filed March 2, 2026) under Item 8.01 to announce a press release titled “DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting.” The press release, dated February 28, 2026, summarizes additional data from the company’s Phase 3 VITESSE clinical study and notes presentation activity at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting.

Key Details

• Press release title: “DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting.”
• Press release date: February 28, 2026; Form 8-K filed: March 2, 2026.
• Exhibit: Press release is attached to the 8-K as Exhibit 99.1.
• Form 8-K signed by Virginie Boucinha, Chief Financial Officer of DBV Technologies.

Why It Matters
This filing signals clinical progress and public dissemination of additional Phase 3 data—information investors watch closely because Phase 3 results can affect regulatory outlook, future commercial potential, and valuation. The 8-K itself contains the press release rather than new financial statements or agreements, so investors should review the attached release and any conference materials or abstracts for specific efficacy, safety, or regulatory details.